


**Pre-ESH Athens 2022 Satellite Symposium**

---



**A roadmap to future  
European Hypertension  
Guidelines**

September 25-26, 2021

---

**SCIENTIFIC PROGRAMME**

# SEPTEMBER 25

Chairs of the Meeting: R. Kreutz, G. Mancia, K. Tsioufis

## 08.00 - 09.15 Hypertension Definition/CV risk calculation

Chairs: C. Borghi - E. Lurbe

08.00	Classification of BP and definition of hypertension – Need for change?	R. Cifková
08.15	CV risk calculation and calculators - factors to be considered	P. Whelton
08.30	Hypertension-mediated organ damage. What is new and needs to be changed	E. Agabiti-Rosei
08.45 – 09.15	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 09.20 - 10.30 BP measurements

Chairs: G. Grassi - D. Lovic

09.20	How to measure office BP. The attended or unattended approach?	G. Stergiou
09.35	Out-of-office BP. Optional or mandatory?	G. Mancia
09.50	Other BPs and devices. Potential and limitations	R. McManus
10:00 – 10.30	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 10.30- 10.45 **BREAK**

## 10.45 – 11:55 Threshold and target BP values for intention and treatment

Chairs: G. Grassi – B. Spronck

10.45	Office BP threshold	A. Persu
11.00	Office BP target for treatment	R. Kreutz
11.15	Reference out-of-office BP threshold and target	G. Parati
11.25 – 11.55	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 12.00 - 12.50 Non-pharmacological treatment

Chairs: M. Dorobantu - A.M Heagerty

12:00	Salt reduction - General recommendations or specific threshold and target?	J. Polonia
12.15	Do we have sufficient evidence to introduce new lifestyle approaches?	A. Schutte
12.30 – 12.50	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 12.50 - 13.30 **BREAK**

# SEPTEMBER 25

## **13.30 - 14.30 SATELLITE WEBINAR supported by Servier**

### **Is adherence to treatment the last unmet medical need in hypertension?**

13.30	Introduction	R. Kreutz
13.32	Non-adherence: the enemy of treatment efficacy	K. Narkiewicz
13.42	Time to act together for a global initiative to improve patient adherence	M. Burnier
13.52	Conclusion	A. Pathak
14.00 – 14.30	General Discussion on the topics above mentioned R. Kreutz - K. Narkiewicz - M. Burnier - A. Pathak - A. Persu - J. Polonia	

## **14.45 - 16.00 Drug treatment strategies. Are some changes needed?**

Chairs: D. Clement - B. Jelakovic

14.45	Initial dual combination	F. Messerli
15.00	Triple Therapy	T. Kahan
15.15	Single pill combination	K. Narkiewicz
15.30 – 16.00	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## **16.00 - 16.15 BREAK**

## **16.15 - 17.15 SATELLITE WEBINAR supported by Medtronic**

### **Renal Denervation: The Third Pillar for Hypertension Management?**

16.15	Introduction and Welcome	R. E. Schmieder
16.20	From Pilot to Real World Registry – The SPYRAL clinical program	F. Mahfoud
16.30	Guideline Evolution: Updates on latest renal denervation consensus statements	K. Tsioufis
16.45	The Future of Renal Denervation in the treatment pathway of hypertension F. Mahfoud - K. Tsioufis - R. Schmieder	
17.05 – 17.15	Q&A and wrap up	R. E. Schmieder

## **17.30 - 18.40 Antihypertensive drugs. Controversial aspects**

Chairs: J. Brgulian - A. Coca

17.30	Thiazides vs Thiazides-like	M. Burnier
17.40	ACE-Inhibitors vs ARBs	S. Laurent
17.50	Dual combinations: RAS blockers with CCB or D?	S.E. Kjeldsen
18.00	Dual combinations: Should RAS blockers be the backbone of every combination?	T. Unger
18.10 – 18.40	General Discussion on the topics above mentioned (with in house and remote discussants*)	

# SEPTEMBER 26

## 08.00 - 09.05 Device-based therapy

Chairs: M. Azizi – A. Pathak

08.00	Update on clinical trials on renal denervation	M. Azizi
08.15	Registry and other contributions	F. Mahfoud
08.25	Positioning in guidelines	K. Tsioufis
08.35	Other device-based treatments	T. Weber
08.45 - 09.05	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 09.10 - 10.55 Specific Clinical Conditions I

Chairs: M. Arici - P. Van de Borne

09.10	White coat and masked hypertension	P. Palatini
09.25	Discussion (with in house and remote discussants*)	
09.35	Drug treatment of resistant hypertension - Should spironolactone still be the preferred drug?	B. Williams
09.45	Drug treatment of resistant hypertension - Novel drugs	M. Brown
09.55	Discussion (with in house and remote discussants*)	
10.05	The elderly frail patient	A. Benetos
10.20	Discussion (with in house and remote discussants*)	
10.30	Should the antihypertensive drug treatment strategy differ in diabetes from the core-strategy?	J. Redon
10.45 - 10.55	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 10.55 - 11.10 BREAK

## 11.10 - 12.30 Specific Clinical Conditions II

Chairs: V. Kotsis – M. Tomaszewski

11.10	Heart failure with preserved ejection fraction	A. Kasiakogias
11.20	Discussion (with in house and remote discussants*)	
11.30	Atrial fibrillation – How to measure BP and what is the BP target	A. Manolis
11.40	Discussion (with in house and remote discussants*)	
11.50	Management of diabetic and non-diabetic chronic kidney disease	P. Sarafidis
12.00	Discussion (with in house and remote discussants*)	
12.10	Impact of new antidiabetic agents in heart failure and CKD	R. Schmieder
12.20 - 12.30	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 12.30 - 13.15 BREAK

# SEPTEMBER 26

## 13.15 - 14.15 SATELLITE WEBINAR supported by MERCK

### Beta blocker class effect: Truth or Myth?

13.15	How correct is it to say that beta-blockers have a class effect?	S. Kjeldsen
13.30	The power of multi-modal BP control in a single pill: The value of new SPCs in hypertension	F. Mahfoud
13.45	Beta blockers in the hypertension guidelines: where do we stand?	G. Mancia
14.00 - 14.15	General Discussion on the topics above mentioned	

## 14.30 - 15.30 Methodological aspects

Chairs: A. Dominiczak – R.M. Touyz

14.30	Meta-analysis. Still top evidence and which types of meta-analyses?	C. Thomopoulos
14.45	Real world evidence. Upgrading and potential for future research	M. Brunström
15.00	Class and strength of recommendations. Is simplification desirable?	N. Poulter
15.10 - 15.30	General Discussion on the topics above mentioned (with in house and remote discussants*)	

## 15.30 - 15.45 BREAK

## 15.45 - 16.45 SATELLITE WEBINAR supported by Omron

### Home blood pressure monitoring – Its advantages and future perspectives

	Opening remarks	B. Williams
15.45	Advantages of HBPM and current positioning in the guidelines	B. Williams
15.55	Nocturnal blood pressure measured by home devices: evidence and perspective for clinical application	G. Parati
16.15	Telemonitoring and self-management in the control of hypertension	R. McManus
16.35 - 16.45	General Discussion on the topics above mentioned	

## 17.00 - 18.15 Other issues (to be introduced by a short explanatory statement)

17:00	Chairs: A. Januszewicz - A.H.J. Danser	
17:05	Use of genetic testing	A. Dominiczak
17:10	Isolated diastolic hypertension	C. Delles
17:15	Heart rate	P. Palatini
17:20	Concise or long explanatory document?	A.M. Heagerty
17:25	Hypertension emergencies & urgencies	M.L. Muiesan
17:30	Perioperative hypertension	A. Manolis
17:35	The gap between BP threshold and target	V. Ram
17:40	Which lower age cut-off should be considered?	E. Lurbe
17:45	How to position primary aldosteronism	P. Mulatero
17:50	Bed time antihypertensive drug dosing	S.E. Kjeldsen
18:55 - 18.15	General Discussion on the topics above mentioned (with in house and remote discussants*)	

### \*Remote Experts/discussants:

M. Weber; J. Wang; P. Whelton; M. Schlaich; V. Ram; P. Lopez-Jaramillo; M. Esler; A Schutte